For Institutions
About
The FDA has approved GSK's Exdensur (depemokimab-ulaa) for severe eosinophilic asthma in patients aged 12 and older, based on Phase 3 trials showing up to 58% fewer asthma attacks with twice-yearly dosing. GSK shares rose 1.21% to $49.37, nearing a 52-week high.
Goldman Sachs analyst Rajan Sharma maintains a Hold rating for GlaxoSmithKline with a £17.00 price target. Sharma, a 3-star analyst, has a 3.3% average return and a 57.78% success rate. Deutsche Bank also issued a Hold rating, while HSBC maintained a Sell rating for GSK.
Health care stocks are advancing premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF up 0.1% and the iShares Biotechnology ETF up 0.7%. GSK shares rose over 1% following FDA approval for a new asthma treatment. Sagimet Biosciences' stock increased by more than 3% after a licensing agreement with TAPI Technology. Compugen shares surged over 13% after amending a license agreement with AstraZeneca.
UK stocks are expected to open flat on December 17. Key updates include BAE Systems reducing its stake in Air Astana, GSK receiving FDA approval for an asthma treatment, Airtel Africa partnering with SpaceX, and British employers planning 3% pay settlements next year. Oil prices rose due to U.S. sanctions on Venezuela, while gold and copper prices increased amid U.S. job market data. The FTSE 100 closed lower, influenced by energy and defense stock losses and expectations of a Bank of England interest rate cut.
GSK's asthma drug Exdensur (depemokimab) has gained approvals from the UK MHRA and U.S. FDA as an add-on treatment for severe asthma, with a twice-yearly dosing schedule.123On December 16, 2025, GSK plc bought back 13.6 million shares, raising its treasury shares to 239.1 million. Total shares issued, excluding treasury, is 4.1 billion.4
